Brief: Eqt Life Sciences' Imcheck Therapeutics To Be Acquired By Ipsen
Oct 22 (Reuters) - EQT AB EQTAB.ST: EQT LIFE SCIENCES' IMCHECK THERAPEUTICS TO BE ACQUIRED BY IPSEN IN A TRANSACTION VALUED AT UP TO EUR 1 BILLION IMCHECK SHAREHOLDERS TO RECEIVE EUR 350 MILLION, TOTAL UP TO EUR 1 BILLION DEAL EXPECTED TO CLOSE BY END OF Q1 2026 Source text: ID:nWkrbPWzwC Further company coverage: EQTAB.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients